Novartis has significantly strengthened its neuroscience pipeline over recent years, topped by the $12bn acquisition of Avidity Biosciences set to close later this year.

Our research purpose is developing new molecular technology based on live-cell organic chemistry that can selectively label and modify target proteins under natural habitats. We also aim to develop ...